Introduction {#section5-1470320316643903}
============

Essential hypertension is a common risk factor for cardiovascular diseases (CVDs). Except for lifestyle modification, drug therapy is the main treatment strategy. A single-pill combination (SPC) of two drugs is recommended by several recent international guidelines for hypertension,^[@bibr1-1470320316643903],[@bibr2-1470320316643903]^ including the Chinese guidelines of 2010^[@bibr3-1470320316643903]^ for the treatment of hypertension in high-risk patients who require marked blood pressure (BP) reductions. The China STATUS II (Survey of hyperTensive pAtienTs blood pressUre control rate in clinic Service) is a prospective, multicentre, open-label, post-marketing, observational study; including 11,312 Chinese adults (aged ⩾ 18 years) with essential hypertension, who were prescribed a once-daily valsartan/amlodipine (Val/Aml, 80/5 mg) SPC. China STATUS II is the first evidence-based, real-world data in Chinese hypertensive patients, which shows the efficacy and safety of the Val/Aml SPC.^[@bibr4-1470320316643903]^

It is well known that young adult women have lower BP than age-matched men; but the prevalence of CVDs, including hypertension in women, increases rapidly after the onset of menopause. Recent studies show a few possible causes for gender-related differences in CVDs, such as: The change in female hormonal status and the loss of cardiovascular protection provided by oestrogen.^[@bibr5-1470320316643903][@bibr6-1470320316643903]--[@bibr7-1470320316643903]^ Although numerous studies report gender-related differences in the regulation of arterial pressure and renal function by the renin-angiotensin system (RAS)^[@bibr8-1470320316643903][@bibr9-1470320316643903]--[@bibr10-1470320316643903]^ and the response to RAS inhibition,^[@bibr11-1470320316643903][@bibr12-1470320316643903]--[@bibr13-1470320316643903]^ there is no mention of the selection of antihypertensive drugs based on gender, except in pregnancy-related situations, in any of the guidelines worldwide. Moreover, insufficient gender-specific data has been provided by clinical trials,^[@bibr14-1470320316643903]^ making it difficult to optimise drug selection for both genders. In order to understand gender differences in BP management, we examined the effect of gender on the efficacy of Val/Aml SPC in the China STATUS II study.

Methods {#section6-1470320316643903}
=======

Study design and participants {#section7-1470320316643903}
-----------------------------

The study design for China STATUS II has been reported elsewhere.^[@bibr4-1470320316643903]^ To summarise, China STATUS II was a multicentre, post-marketing, prospective, observational study, which enrolled 11,312 adult Chinese patients with essential hypertension whose BP was not adequately controlled by monotherapy.

All enrolled patients had a mean sitting systolic BP (SBP) ⩾ 140 mm Hg (⩾ 130 mm Hg for diabetes or chronic kidney disease (CKD)) and/or a mean sitting diastolic BP (DBP) ⩾ 90 mm Hg (⩾ 80 mm Hg for diabetes or CKD), whose BP was inadequately controlled by monotherapy. Before enrolment, all patients provided written informed consent. The study complied with the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and applicable local regulations in China, and was approved by the Ethical Review Committee of the First Hospital of Harbin Medical University. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1975, as revised in 2000 and 2008.

The baseline characteristics of the randomised patients are described in the report of the China STATUS II study's main findings.^[@bibr4-1470320316643903]^

Eligible patients from 238 regional centres across 29 provinces of China were enrolled from 12 October 2010 to 20 February 2012. After enrolment, there was no dietary, lifestyle nor medication change in all subjects. The lifestyle questionnaires included questions on education and socioeconomic status, occupation, history of previous illness and disorders or surgical operations, lifetime history of consumption of tobacco and alcoholic beverages, and physical activity. All patients who had stopped taking other antihypertensive drugs received Val/Aml 80/5 mg SPC for 4 weeks, instead of their previous antihypertensive drugs. The initial BP target (\< 140/90 mm Hg (or \< 130/80 mm Hg for diabetes or CKD)) was unified to \< 140/90 mm Hg, for easier management. The treatment was in accordance with the routine clinical outpatient practice in China. The study duration was 8 weeks, with a follow-up every 4 weeks. If a patient did not achieve BP control at the end of 4 weeks of the SPC, an additional antihypertensive agent could be added, according to the physician's decision.

Statistical analysis {#section8-1470320316643903}
--------------------

All statistical analyses were performed using SAS^®^ software version 9.2 (SAS Institute Inc., Cary, NC, USA), with a 2-sided significance level (*p*) of \< 0.05. Demographic and baseline variables were summarised using descriptive statistics, including the mean, SD, median, minimum and maximum values for numeric variables; and the count number and percentage for the categorical variables. We used the *T* test, chi-square test and Fisher accurate probability test.

We estimated the changes in SBP and DBP at 4 and 8 weeks for gender and age as fixed effects, by using SAS PROC MIXED (SAS Institute, Cary, NC, USA).^[@bibr15-1470320316643903]^ For the analysis in Mixed Model 1, we calculated variance components for the baseline BP, their BMI, smoking, drinking, exercise and education level, using gender and age as fixed effects. The same analysis was then used in Mixed Model 2, adjusting for the baseline BP and statistically significant effects in Model 1.

Results {#section9-1470320316643903}
=======

Demographic and baseline characteristics {#section10-1470320316643903}
----------------------------------------

The detailed demographic and baseline characteristics of the patients are presented in [Table 1](#table1-1470320316643903){ref-type="table"}. We analysed a total of 11,312 patients (6456 (57%) men and 4856 (43%) women). At enrolment, the men were younger in age (*p* \< 0.001) and had a higher BMI (*p* \< 0.001) than women. Compared with the female patients, we observed a higher educational background, more physical activity, and more smoking and drinking in the male patients (*p* \< 0.05). There were no significant differences in their present cardiovascular risk factors and medical history, and their previous use of antihypertensive drug classes, between these men and women ([Table 1](#table1-1470320316643903){ref-type="table"}).

###### 

Demographic and baseline characteristics of the study patients (*n* = 11,312).^[a](#table-fn1-1470320316643903){ref-type="table-fn"}^

![](10.1177_1470320316643903-table1)

                                                                                                  Men (*n* = 6456)   Women (*n* = 4856)   *p*-value
  ----------------------------------------------------------------------------------------------- ------------------ -------------------- -----------
  Mean age (SD)                                                                                   57.4 (14.27)       59.8 (13.09)         \< 0.001
  Patients in each group, *n* (%)                                                                                                         \< 0.0001
   \< 55 years old                                                                                2913 (45.12%)      1798 (37.03%)        
   55--64 years old                                                                               1641 (25.42%)      1351 (27.82%)        
   65--74 years old                                                                               1019 (15.78%)      1015 (20.90%)        
   ⩾ 75 years old                                                                                 883 (13.68%)       692 (14.25%)         
  BMI (kg/m^2^)                                                                                   25.0 (2.95)        24.3 (3.34)          \< 0.001
  BMI ⩾ 25 kg/m^2^, *n* (%)                                                                       3088 (47.9%)       1824 (37.6%)         \< 0.0001
  Ethnicity, *n* (%)                                                                                                                      0.3074
   Han                                                                                            6262 (96.9%)       4727 (97.3%)         
   Hui                                                                                            98 (1.51%)         78 (1.60%)           
   Manchu                                                                                         38 (0.58%)         22 (0.45%)           
   Mongolian                                                                                      18 (0.27%)         7 (0.14%)            
   other                                                                                          40 (0.61%)         22 (0.45%)           
  SBP (SD), mm Hg                                                                                 159.3 (12.31)      160.0 (12.71)        0.003
  DBP (SD), mm Hg                                                                                 96.4 (10.65)       94.5 (10.72)         \< 0.001
  Heart rate (SD), bpm                                                                            75.6 ( 7.74)       75.2 (8.00)          0.003
  Current smoker, *n* (%)                                                                         2090 (32.3%)       94 (1.93%)           \< 0.0001
  Current alcohol drinker, *n* (%)                                                                1446 (22.3%)       50 (1.02%)           \< 0.0001
  College degree or above, *n* (%)                                                                1615 (25.0%)       630 (12.9%)          \< 0.0001
  Appropriate physical activity^[b](#table-fn2-1470320316643903){ref-type="table-fn"}^, *n* (%)   4908 (76.0%)       3607 (74.2%)         0.0334
  Present cardiovascular risk factors or medical history, *n* (%)                                                                         
   Dyslipidemia                                                                                   1588 (24.5%)       1114 (22.9%)         0.1136
   Diabetes                                                                                       1038 (16.0%)       827 (17.0%)          0.3029
   CHD                                                                                            957 (14.8%)        796 (16.3%)          0.0726
   Heart failure                                                                                  104 (1.61%)        85 (1.75%)           0.6971
   Kidney disease                                                                                 206 (3.19%)        149 (3.06%)          0.9317
  Previous antihypertensive drug classes, *n* (%)                                                                                         0.9889
   β-Blockers                                                                                     518 (8.02%)        385 (7.92%)          
   CCBs                                                                                           3083 (47.7%)       2330 (47.9%)         
   ACEIs                                                                                          994 (15.3%)        734 (15.1%)          
   Diuretics                                                                                      181 (2.80%)        140 (2.88%)          
   ARB                                                                                            1630(25.2%)        1223(25.1%)          
   Others                                                                                         44 (0.68%)         38 (0.78%)           
   Unknown                                                                                        6 (0.09%)          6 (0.12%)            

We used the *T* test for mean age, mean height, mean weight, BMI, SBP, DBP and heart rate; Chi square test for patients in each group: BMI ⩾ 25, ethnicity, current smoker, current alcohol drinker, college degree or above, appropriate physical activity, present risk factors of medical history related to cardiovascular disease, and previous anti-hypertensive drug classes used.

ACEI: ACE inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; BPM: beats per minute; CCB: calcium channel blocker; DBP:diastolic blood pressure; mm Hg: millimetres of mercury as units of pressure; SBP: systolic blood pressure.

Appropriate physical activity (if the subject participates in any regular physical activities, such as walking, swimming, running, etc.).

Blood pressure during follow-up {#section11-1470320316643903}
-------------------------------

SBP was higher in the female patients versus the male patients (160.0 ± 12.71 versus 159.3 ± 12.31 mm Hg; *p* = 0.003); whereas DBP was higher in male patients versus female patients, at enrolment (96.4 ± 10.65 versus 94.5 ± 10.72 mm Hg; *p* \< 0.001).

After the treatment, a significantly lower proportion of women did not achieve the target BP, compared with men (57.41% versus 59.59%, *p* \< 0.05 at 4 weeks; and 22.22% versus 23.78%, *p* \< 0.05, at 8 weeks). In order to examine the effect of age on drug efficacy, both genders were divided into four different age groups: \< 55, 55--64, 65--75 and \> 75 years. As a result, for all enrolled patients, the proportion of patients not achieving the target SBP increased with age; however, the proportion of patients not achieving the target DBP was the opposite ([Figure 1](#fig1-1470320316643903){ref-type="fig"}).

![The proportion of patients not achieving the target SBP of \< 140 mm Hg in different age groups of men and women, respectively; at baseline, 4 weeks and 8 weeks after their treatment with the Val/Aml combination therapy.](10.1177_1470320316643903-fig1){#fig1-1470320316643903}

![The proportion of patients not achieving the target diastolic blood pressure (DBP) of \< 90 mmHg in different age groups of men and women, respectively: at baseline, 4 weeks and 8 weeks after their treatment with the Val/Aml combination therapy.\
Aml: amlodipine; DBP: diastolic blood pressure; mmHg: millimetres of mercury; SBP: systolic blood pressure; Val: valsartan.](10.1177_1470320316643903-fig2){#fig2-1470320316643903}

The next assessment included the changes in SBP and DBP at 4 and 8 weeks after treatment, according to gender and age, by using SAS PROC MIXED. The *p* values obtained from the Mixed Model were as follows: Changes in SBP at 4 weeks, *p* \< 0.0001 for gender and *p* = 0.3832 for age; changes in SBP at 8 weeks, *p* = 0.0026 for gender and *p* = 0.0225 for age; changes in DBP at 4 weeks, *p* = 0.0602 for gender and *p* = 0.0219 for age; changes in DBP at 8 weeks, *p* = 0.1035 for gender and *p* = 0.0057 for age. In the Mixed Model 1 analysis, age and gender were fixed effects and the baseline BP, BMI, smoking, drinking, exercise and education level were random effects. There was no significant correlation between the patients' age, gender, BMI, smoking, drinking, exercise and education level.

The Mixed Model 2 was adjusted for the baseline BP and statistically significant effects in the Model 1. That mixed model showed that the changes in SBP were closely related to gender. Given that the proportion of the women who did not achieve the target BP was lower as compared with the men in this study, the SBP-lowering effect of the Val/Aml treatment might be better in women. In addition, the changes in DBP were closely related to age. These findings were consistent in both Mixed Model 1 and Mixed Model 2 ([Table 2](#table2-1470320316643903){ref-type="table"}).

###### 

Changes in SBP and DBP at 4 weeks and 8 weeks, according to gender and age, using SAS PROC MIXED analysis using the mixed model, with the age group and gender as fixed factors and the baseline BP at 4 weeks and 8 weeks as a covariate.

![](10.1177_1470320316643903-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                           \< 55 years of age   55 years to \< 64 years   65 years to \< 75 years   \> 75 years                                                      *p* value (age)
  ------------------------------------ ------------------------------------------------------------------- -------------------- ------------------------- ------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  *n* (men and women study subjects)   2917/1798                                                           1641/1351            1019/1015                 883/692                                                                                    

  SBP (mm Hg)                                                                                                                                                                                                                                        

  Baseline                             men                                                                 158.2 ± 12.40        159.3 ± 11.92             160.6 ± 12.04             161.3 ± 12.67                                                    \< 0.0001

                                       women                                                               158.4 ± 12.07        160.1 ± 12.54             161.6 ± 13.34             161.6 ± 13.23                                                    

  *p* value (gender)                   0.0041                                                                                                                                                                                                        

  Differences at 4 weeks               men                                                                 − 19.1 ± 11.10       − 19.7 ±\                 − 20.2 ±\                 − 20.4 ± 11.12                                                   0.3832
                                                                                                                                10.94                     11.07                                                                                      

  women                                − 19.6 ±\                                                           − 21.1 ±\            − 21.6 ±\                 − 21.6 ± 11.97            0.7305^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\   
                                       11.29                                                               12.28                12.54                                               0.6889^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^    

  *p* value (gender)                   \< 0.0001\                                                                                                                                                                                                    
                                       \< 0.0001^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\                                                                                                                                             
                                       \< 0.0001^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^                                                                                                                                              

  Differences at 8 weeks               men                                                                 26.1 ± 11.97         26.9 ± 11.75              −27.3 ±\                  − 27.9 ± 12.10                                                   0.0225
                                                                                                                                                          11.86                                                                                      

                                       women                                                               26.6 ± 12.07         27.8 ± 12.64              28.7 ± 13.19              − 28.6 ± 12.51                                                   0.0858^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\
                                                                                                                                                                                                                                                     0.0225^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^

  *p* value (gender)                   0.0026\                                                                                                                                                                                                       
                                       0.0023^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\                                                                                                                                                
                                       0.0026^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^                                                                                                                                                 

  DBP (mm Hg)                                                                                                                                                                                                                                        

  Baseline                             men                                                                 98.6 ± 9.97          96.2 ± 9.78               94.6 ± 10.53              91.4 ± 12.27                                                     \< 0.0001

                                       women                                                               96.7 ± 9.71          94.6 ± 10.31              93.0 ± 11.29              90.4 ± 11.64                                                     

  *p* value (gender)                   \< 0.0001                                                                                                                                                                                                     

  Differences at 4 weeks               men                                                                 12.0 ± 8.54          10.7 ± 7.66               10.1 ± 8.36               − 8.7 ± 8.13                                                     0.0219

  women                                10.7 ± 8.01                                                         10.8 ± 8.61          9.6 ± 8.60                − 8.6 ± 8.90              0.0206^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\   
                                                                                                                                                                                    0.0166^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^    

  *p* value (gender)                   0.0602\                                                                                                                                                                                                       
                                       0.0206^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\                                                                                                                                                
                                       0.0403^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^                                                                                                                                                 

  Differences at 8 weeks               men                                                                 17.0 ± 9.37          15.5 ± 8.56               14.4 ± 9.20               − 12.8 ± 9.22                                                    0.0057

  women                                15.7 ± 9.03                                                         14.9 ± 9.40          13.6 ± 9.51               − 12.5 ± 9.87             0.0601^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\   
                                                                                                                                                                                    0.0023^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^    

  *p* value (gender)                   0.1035\                                                                                                                                                                                                       
                                       0.8275^[a](#table-fn4-1470320316643903){ref-type="table-fn"}^\                                                                                                                                                
                                       0.0771^[b](#table-fn5-1470320316643903){ref-type="table-fn"}^                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Analysis using the Mixed Model 1, age and gender as a fixed effects, adjusted for the baseline of BP, BMI, smoking, drinking, exercise and education level.

Analysis using the Mixed Model 2, adjusted for the baseline BP and statistically significant effects in Model 1. BP changes at 4 weeks and 8 weeks, after being adjusted for baseline BP and exercise.

BMI: body mass index; BP: blood pressure; DBP: diastolic blood pressure; mm Hg: millimetres of mercury as units of pressure; SBP: systolic blood pressure.

Discussion {#section12-1470320316643903}
==========

One major finding of our study was that a gender difference existed in the treatment response to Val/Aml among Chinese hypertension patients, indicating that this therapy might show better SBP-lowering effects in women.

Major gender differences exist in the development and progression of hypertension and CVD. Before menopause, women usually have lower BP and less hypertension and CVD, relative to age-matched men^[@bibr16-1470320316643903],[@bibr17-1470320316643903]^; however, this cardiovascular protection in women is lost after menopause.^[@bibr18-1470320316643903]^ Several studies confirm that gender differences exist in terms of the pharmacokinetic and pharmacodynamic characteristics of drugs.^[@bibr19-1470320316643903][@bibr20-1470320316643903]--[@bibr21-1470320316643903]^ Wing et al.^[@bibr22-1470320316643903]^ shows that treatment with angiotensin-converting enzyme (ACE) inhibitors correlates with a better outcome, compared with treatment with diuretics; whereas another study concludes that the response to specific treatment agents appears to differ between men and women.^[@bibr23-1470320316643903]^ These findings also suggested that antihypertensive regimens need to be tailored according to gender. Some might argue that female patients are always more aware of the need for treatment and show better compliance; thus, could get a better BP-lowering effect. We also evaluated both the physician and patients' self-compliance assessments, and found that there were no significant differences between the male and female genders (*p* = 0.7517 and *p* = 0.0702, respectively). Also, given that the longitudinal BP response was appropriate in both men and women and that the study length was short, we did not consider male patients lacking compliance in our study. Although the cause for these gender-related differences in response to therapy is not certain, these gender differences are associated with sexual dimorphism in the physiological mechanisms that regulate arterial pressure, which can impact the male and female patients' responses to different therapeutic approaches.^[@bibr24-1470320316643903]^

Notably, gender-related differences also exist in the RAS, due to differential modulation by sex hormones.^[@bibr25-1470320316643903],[@bibr26-1470320316643903]^ In our study, most patients were aged \> 55 years (6601/11,312 (58%)); and of these, 46% (3058/6601) of them were women. Given that the mean post-menopausal age is 56 years in China,^[@bibr27-1470320316643903]^ quite a few women in our study were in the post-menopausal period. Oestrogen regulates all components of the RAS, increasing the synthesis of angiotensinogen, while decreasing the synthesis and activity of renin and ACE. Oestrogen decreases the expression of the angiotensin Type 1 receptor (AT~1~R) in target tissue, but increases the expression of Type 2 receptor AT~2~R.^[@bibr28-1470320316643903],[@bibr29-1470320316643903]^ Studies in animal models show that oestrogen and RAS blockade may act synergistically to downregulate the AT~1~R.^[@bibr30-1470320316643903],[@bibr31-1470320316643903]^ Since valsartan is an angiotensin II receptor blocker (ARB), the Val/Aml combination therapy might inhibit RAS activation and provide a better antihypertensive effect for post-menopausal women. A small study among 51 post-menopausal hypertensive women showed that the BP-lowering effect of the ARB irbesartan is augmented by co-administration with 17-estradiol, suggesting there are potentiating effects of the two different antihypertensive mechanisms.^[@bibr32-1470320316643903]^ Of course, further study into the mechanisms of the gender differences in hypertension treatment is needed.

Another finding of our study was that for all of the enrolled patients, the proportion of patients not achieving the target SBP (⩽ 140 mm Hg) increased with age; however, the proportion of patients not achieving the target DBP (⩽ 90 mm Hg) was the opposite.

Elevated BP is an important cardiovascular risk factor. Although the target DBP and SBP are defined by guidelines, DBP has historically taken precedence in hypertension management; however, there is strong evidence that SBP is superior to DBP as a predictor of cardiovascular events, particularly in the elderly.^[@bibr33-1470320316643903]^ Stamler et al.^[@bibr34-1470320316643903]^ found that SBP has a stronger association with cardiovascular risk, as compared with DBP, in middle-aged and elderly individuals. Moreover, the superior predictive ability of SBP was also confirmed in a meta-analysis of 61 prospective observational studies that recorded BP and cause-specific mortality.^[@bibr35-1470320316643903]^ With an increasing proportion of aging population, the prevalence of hypertension and related cardiovascular morbidity in Asian patients continues to rise, placing a substantial and escalating social and economic burden on this region.^[@bibr36-1470320316643903]^ The prevalence of hypertension in the Chinese population is 39% overall, 59.4% in those aged \> 60 years and 72.8% in those aged \> 75 years.^[@bibr37-1470320316643903]^ The age-specific prevalence of hypertension increased with age, throughout the age range. In our study, the mean age of the male patients was 57.4 ± 14.27 years and that of female patients was 59.8 ± 13.09 years. The proportion of patients who did not achieve the target SBP increased with age. An elevated SBP increases the risk of CVD, mortality and renal function decline, and that risk may increase at lower SBP levels in the Asian than in the Western population. Hence, reducing SBP should be the primary goal in the management of hypertension, particularly as the patients age.^[@bibr38-1470320316643903]^

There were several limitations in our study. First, the focus was only on short-term BP lowering. The long-term clinical outcomes might be more important in elucidating gender differences and cardiovascular events. Besides, 686 (6.06%) of the subjects of this study had to take additional antihypertensive agents to control their BP. The most used combined antihypertensive agents were metoprolol (1.67%) and hydrochlorothiazide (1.45%). Because the majority (10,626 out of 11,312 (93.94%)) of the subjects in this study received only Val/Aml SPC for BP control, we consider that the potential impact of additional antihypertensive treatment on the BP outcome is limited. We will avoid this kind of possible bias in future studies. Moreover, we did not control or monitor the patients' sodium or protein intake, although that could be extremely difficult to implement in such a large-scale observational study.

Conclusions {#section13-1470320316643903}
===========

For all the patients enrolled in our study, the proportion of patients not achieving the target SBP increased with age; however, the proportion not achieving the target DBP was the opposite. Although the mechanisms responsible for gender differences in the treatment response to Val/Aml among Chinese patients were not addressed, our findings indicated that women might have a better SBP-lowering effect with such therapy. Gender might be a factor for consideration in the decision-making process of individualised antihypertensive therapy, in the future.
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